BNT24002

BNT24002 is a proprietary sublingual (thin-film) formulation of cladribine developed by BioNxt for the treatment of lupus nephritis, a severe autoimmune condition that can lead to kidney failure. This innovative drug delivery system is designed to maximize bioavailability and minimize side effects by bypassing the gastrointestinal tract and first-pass liver metabolism, resulting in higher absorption and more consistent therapeutic effects. The sublingual film dissolves quickly in the mouth, providing a non-invasive alternative for patients who may have difficulty with oral medications or injections. BNT24002 targets an orphan disease population with limited treatment options and aims to improve patient compliance and outcomes through its advanced delivery technology[1][9][10].